Predicting resistance to brain tumor chemotherapy

December 12, 2011

Glioblastoma multiforme (GBM) is the most common and lethal of all human brain tumors that originate in the brain. For most patients, treatment involves surgery followed by both radiation therapy and chemotherapy with temozolomide. However, many GBMs are resistant to the effects of temozolomide. A team of researchers led by Sameer Agnihotri, at the University of Toronto, Toronto, has now determined that the protein APNG can contribute to GBM resistance to the effects of temozolomide. Importantly, high levels of expression of APNG in the nucleus of ressected tumor cells correlated with poorer overall survival compared with patients lacking APNG expression. Agnihotri, and colleagues therefore suggest that monitoring APNG levels could provide insight into whether or not a patient with GBM will respond to temozolomide, although this awaits confirmation in predictive and prospective studies.
-end-
TITLE: Alkylpurine-DNA-N-glycosylase confers resistance to temozolomide in xenograft models of glioblastoma multiforme and is associated with poor survival in patients

AUTHOR CONTACT:
Sameer Agnihotri
Hospital for Sick Children Research Institute, University of
Toronto, Toronto, Ontario, Canada.
Phone: 416-813-6688; Fax: 416-813-8456; E-mail: sameer.agnihotri@utoronto.ca.

JCI Journals

Related Chemotherapy Articles from Brightsurf:

Chemotherapy is used to treat less than 25% of people with localized sarcoma
UCLA researchers have found that chemotherapy is not commonly used when treating adults with localized sarcoma, a rare type of cancer of the soft tissues or bone.

Starved cancer cells became more sensitive to chemotherapy
By preventing sugar uptake, researchers succeeded in increasing the cancer cells' sensitivity to chemotherapeutic treatment.

Vitamin D could help mitigate chemotherapy side effects
New findings by University of South Australia researchers reveal that Vitamin D could potentially mitigate chemotherapy-induced gastrointestinal mucositis and provide relief to cancer patients.

Less chemotherapy may have more benefit in rectal cancer
GI Cancers Symposium: Colorado study of 48 patients with locally advanced rectal cancer receiving neoadjuvant chemotherapy, found that patients receiving lower-than-recommended doses in fact saw their tumors shrink more than patients receiving the full dose.

Male fertility after chemotherapy: New questions raised
Professor Delb├Ęs, who specializes in reproductive toxicology, conducted a pilot study in collaboration with oncologists and fertility specialists from the McGill University Health Centre (MUHC) on a cohort of 13 patients, all survivors of pediatric leukemia and lymphoma.

'Combo' nanoplatforms for chemotherapy
In a paper to be published in the forthcoming issue in NANO, researchers from Harbin Institute of Technology, China have systematically discussed the recent progresses, current challenges and future perspectives of smart graphene-based nanoplatforms for synergistic tumor therapy and bio-imaging.

Nanotechnology improves chemotherapy delivery
Michigan State University scientists have invented a new way to monitor chemotherapy concentrations, which is more effective in keeping patients' treatments within the crucial therapeutic window.

Novel anti-cancer nanomedicine for efficient chemotherapy
Researchers have developed a new anti-cancer nanomedicine for targeted cancer chemotherapy.

Ending needless chemotherapy for breast cancer
A diagnostic test developed at The University of Queensland might soon determine if a breast cancer patient requires chemotherapy or would receive no benefit from this gruelling treatment.

A homing beacon for chemotherapy drugs
Killing tumor cells while sparing their normal counterparts is a central challenge of cancer chemotherapy.

Read More: Chemotherapy News and Chemotherapy Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.